These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 19032710)

  • 1. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics.
    Correll CU; Frederickson AM; Kane JM; Manu P
    Bipolar Disord; 2008 Nov; 10(7):788-97. PubMed ID: 19032710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review.
    De Hert M; Schreurs V; Sweers K; Van Eyck D; Hanssens L; Sinko S; Wampers M; Scheen A; Peuskens J; van Winkel R
    Schizophr Res; 2008 Apr; 101(1-3):295-303. PubMed ID: 18299188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with second generation antipsychotics.
    Vuksan-Ćusa B; Jakovljević M; Sagud M; Mihaljević Peleš A; Marčinko D; Topić R; Mihaljević S; Sertić J
    Psychiatry Res; 2011 Aug; 189(1):21-5. PubMed ID: 21216014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
    Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
    Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea's general population.
    Lee NY; Kim SH; Cho B; Lee YJ; Chang JS; Kang UG; Kim YS; Ahn YM
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1243-9. PubMed ID: 20599461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients.
    Fabrazzo M; Monteleone P; Prisco V; Perris F; Catapano F; Tortorella A; Monteleone AM; Steardo L; Maj M
    Neuropsychobiology; 2015; 72(1):29-36. PubMed ID: 26337616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study.
    Cerit C; Vural M; Bos Gelmez SÜ; Ozten E; Aker AT; Yıldız M
    Psychopharmacol Bull; 2010; 43(4):22-36. PubMed ID: 21240150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
    Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
    Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
    Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses.
    Kelly AC; Sheitman BB; Hamer RM; Rhyne DC; Reed RM; Graham KA; Rau SW; Gilmore JH; Perkins DO; Peebles SS; VanderZwaag CJ; Jarskog LF
    J Clin Psychopharmacol; 2014 Aug; 34(4):441-5. PubMed ID: 24943389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic syndrome and adverse clinical outcomes in patients with bipolar disorder.
    Bai YM; Li CT; Tsai SJ; Tu PC; Chen MH; Su TP
    BMC Psychiatry; 2016 Dec; 16(1):448. PubMed ID: 27978821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia.
    Vuksan-Cusa B; Sagud M; Jakovljevic M; Peles AM; Jaksic N; Mihaljevic S; Zivkovic M; Mikulic SK; Jevtovic S
    Nord J Psychiatry; 2013 Oct; 67(5):320-5. PubMed ID: 23228159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative risk of seizure with use of first- and second-generation antipsychotics in patients with schizophrenia and mood disorders.
    Wu CS; Wang SC; Yeh IJ; Liu SK
    J Clin Psychiatry; 2016 May; 77(5):e573-9. PubMed ID: 27249081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.
    Fleischhacker WW; Siu CO; Bodén R; Pappadopulos E; Karayal ON; Kahn RS;
    Int J Neuropsychopharmacol; 2013 Jun; 16(5):987-95. PubMed ID: 23253821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis.
    Vancampfort D; Stubbs B; Mitchell AJ; De Hert M; Wampers M; Ward PB; Rosenbaum S; Correll CU
    World Psychiatry; 2015 Oct; 14(3):339-47. PubMed ID: 26407790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial.
    Romo-Nava F; Alvarez-Icaza González D; Fresán-Orellana A; Saracco Alvarez R; Becerra-Palars C; Moreno J; Ontiveros Uribe MP; Berlanga C; Heinze G; Buijs RM
    Bipolar Disord; 2014 Jun; 16(4):410-21. PubMed ID: 24636483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders.
    Abdel Aziz K; Mohd Ahmed H; Stip E; Aly El-Gabry D
    Int Clin Psychopharmacol; 2024 Jul; 39(4):257-266. PubMed ID: 38381917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder.
    Kilbourne AM; Post EP; Bauer MS; Zeber JE; Copeland LA; Good CB; Pincus HA
    J Affect Disord; 2007 Sep; 102(1-3):145-51. PubMed ID: 17276514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.